Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. more
Time Frame | APVO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -57.84% | -2.28% | -0.57% |
1-Month Return | -54.47% | -3.98% | 1.2% |
3-Month Return | -68.85% | -9.71% | 7.56% |
6-Month Return | -85.85% | -3.39% | 11.44% |
1-Year Return | -98.56% | 3.69% | 28.47% |
3-Year Return | -99.97% | 3.78% | 29.51% |
5-Year Return | -99.97% | 39.76% | 90.64% |
10-Year Return | -100% | 106.88% | 203.73% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 32.42M | 4.31M | 12.29M | 3.11M | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":13.29,"profit":true},{"date":"2021-12-31","value":37.91,"profit":true},{"date":"2022-12-31","value":9.6,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 19.93M | 17.85M | 18.99M | 901.00K | 567.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89.59,"profit":true},{"date":"2021-12-31","value":95.32,"profit":true},{"date":"2022-12-31","value":4.52,"profit":true},{"date":"2023-12-31","value":2.85,"profit":true}] |
Gross Profit | 12.50M | (13.54M) | 12.29M | 2.21M | (567.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-108.37,"profit":false},{"date":"2021-12-31","value":98.36,"profit":true},{"date":"2022-12-31","value":17.71,"profit":true},{"date":"2023-12-31","value":-4.54,"profit":false}] |
Gross Margin | 38.54% | (314.30%) | 100.00% | 71.07% | - | [{"date":"2019-12-31","value":38.54,"profit":true},{"date":"2020-12-31","value":-314.3,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.07,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 40.96M | 31.80M | 33.69M | 31.75M | 28.88M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.64,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":77.52,"profit":true},{"date":"2023-12-31","value":70.5,"profit":true}] |
Operating Income | (40.96M) | (27.49M) | (21.40M) | (28.64M) | (28.88M) | [{"date":"2019-12-31","value":-4096200000,"profit":false},{"date":"2020-12-31","value":-2749400000,"profit":false},{"date":"2021-12-31","value":-2140000000,"profit":false},{"date":"2022-12-31","value":-2864100000,"profit":false},{"date":"2023-12-31","value":-2887800000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (43.06M) | (30.92M) | (29.41M) | 7.01M | (18.65M) | [{"date":"2019-12-31","value":-613.97,"profit":false},{"date":"2020-12-31","value":-440.88,"profit":false},{"date":"2021-12-31","value":-419.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-265.9,"profit":false}] |
Income Taxes | (2.62M) | (12.47M) | (2.10M) | (35.66M) | (1.24M) | [{"date":"2019-12-31","value":-261600000,"profit":false},{"date":"2020-12-31","value":-1247500000,"profit":false},{"date":"2021-12-31","value":-209500000,"profit":false},{"date":"2022-12-31","value":-3565500000,"profit":false},{"date":"2023-12-31","value":-123900000,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (44.70M) | (30.92M) | (29.41M) | 7.01M | (17.62M) | [{"date":"2019-12-31","value":-637.27,"profit":false},{"date":"2020-12-31","value":-440.88,"profit":false},{"date":"2021-12-31","value":-419.28,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-251.17,"profit":false}] |
Income From Discontinued Operations | 4.25M | 13.17M | 951.00K | 1.01M | - | [{"date":"2019-12-31","value":32.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.22,"profit":true},{"date":"2022-12-31","value":7.69,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (40.45M) | (18.45M) | (27.31M) | 42.67M | (17.41M) | [{"date":"2019-12-31","value":-94.79,"profit":false},{"date":"2020-12-31","value":-43.24,"profit":false},{"date":"2021-12-31","value":-64.01,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-40.8,"profit":false}] |
EPS (Diluted) | (15.96) | (8.96) | (6.09) | 1.58 | (7.50) | [{"date":"2019-12-31","value":-1010.13,"profit":false},{"date":"2020-12-31","value":-567.09,"profit":false},{"date":"2021-12-31","value":-385.44,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-474.68,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
APVO | |
---|---|
Cash Ratio | 1.32 |
Current Ratio | 1.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
APVO | |
---|---|
ROA (LTM) | -72.75% |
ROE (LTM) | -250.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
APVO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.71 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.29 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
APVO | |
---|---|
Trailing PE | NM |
Forward PE | 3.94 |
P/S (TTM) | 1.61 |
P/B | 0.64 |
Price/FCF | NM |
EV/R | 0.12 |
EV/Ebitda | 0.39 |
PEG | NM |
Aptevo Therapeutics Inc (APVO) share price today is $4.215
Yes, Indians can buy shares of Aptevo Therapeutics Inc (APVO) on Vested. To buy Aptevo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APVO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Aptevo Therapeutics Inc (APVO) via the Vested app. You can start investing in Aptevo Therapeutics Inc (APVO) with a minimum investment of $1.
You can invest in shares of Aptevo Therapeutics Inc (APVO) via Vested in three simple steps:
The 52-week high price of Aptevo Therapeutics Inc (APVO) is $399.6. The 52-week low price of Aptevo Therapeutics Inc (APVO) is $4.08.
The price-to-earnings (P/E) ratio of Aptevo Therapeutics Inc (APVO) is
The price-to-book (P/B) ratio of Aptevo Therapeutics Inc (APVO) is 0.64
The dividend yield of Aptevo Therapeutics Inc (APVO) is 0.00%
The market capitalization of Aptevo Therapeutics Inc (APVO) is $5.01M
The stock symbol (or ticker) of Aptevo Therapeutics Inc is APVO